Sorry!! The article you are trying to read is not available now.
Medivation, Astellas Prostate Cancer Drug Soars in First Weeks on Market
MINYANVILLE ORIGINAL Medivation’s (NASDAQ:MDVN) newly approved prostate cancer drug passed a very early test as initial sales and a bullish forecast for the treatment Xtandi appear to validate expectations that it will become a blockbuster product. In the drug’s first 12 days of sales the drug Xtandi generated revenue of $14 million. What’s more Medivation’s sales partner Astellas Pharma predicted the treatment will produce sales of $100 million by the end of March 2013. If the forecast holds up those numbers would mean the drug will at least meet bullish Wall Street consensus estimates of $225 million in Xtandi’s ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here